CMS Approves NTAP Reimbursement for Molecular Imaging Agent Cytalux
Through a new technology add-on payment (NTAP), the use of Cytalux will reportedly be reimbursed by CMS up to 65 percent of the cost of the molecular imaging agent, which is FDA-approved for intraoperative imaging of ovarian and lung cancer.
The Centers for Medicare and Medicaid Services (CMS) has granted a new technology add-on payment for Cytalux (On Target Laboratories), an intraoperative molecular imaging agent indicated for assessment of lung and ovarian cancer.
The NTAP payment, which goes into effect on October 1, 2023, will reportedly provide hospitals with reimbursement of up to 65 percent of the cost of Cytalux with a maximum payment of $2,762.50, according to On Target Laboratories.
“We are thrilled Cytalux has been granted NTAP for both lung and ovarian cancer indications,” noted Ben Lundgren, the chief executive officer of On Target Laboratories. “This approval reinforces the clinical benefits of Cytalux and will make our technology accessible to more patients.”
On Target Laboratories noted the molecular imaging agent was granted ICD-10-PCS codes in June 2023 and recently issued a level II HCPCS code from CMS to facilitate submission of hospital claims.
(Editor’s note: For related content, see “Cytalux Gets Expanded FDA Approval for Intraoperative Imaging of Lung Cancer.”)
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
FDA Grants Fast Track Designation to Emerging Agent for Brain PET Imaging
June 11th 2025Currently being evaluated in a phase 2b clinical trial, the 18F-RAD101 PET imaging agent garnered the FDA’s fast track designation for distinguishing between recurrent disease and treatment impact for brain metastases derived from solid tumors.
New PSMA PET Prep Product Now Available in the U.S.
June 11th 2025Offering an extended shelf life, the FDA-approved Gozellix, a preparation kit for gallium-68 (68Ga) gozetotide injection, is indicated for use in PSMA PET imaging of prostate cancer patients with suspected recurrence or metastasis.
Can AI Assessment of PET Imaging Predict Treatment Outcomes for Patients with Lymphoma?
June 2nd 2025The use of adjunctive AI software with pre-treatment PET imaging demonstrated over a fourfold higher likelihood of predicting progression-free survival (PFS) in patients being treated for lymphoma, according to a new meta-analysis.
ASCO: Study Reveals Significant Racial/Ethnic Disparities with PSMA PET Use for Patients with mPCa
May 30th 2025Latinx patients with metastatic prostate cancer were 63 percent less likely than non-Hispanic White patients to have PSMA PET scans, according to a study of 550 patients presented at the American Society of Clinical Oncology (ASCO) conference.
